title: Seroreversion in human immunodeficiency virus-exposed but uninfected infants.
abstract: The goal of this study was to describe seroreversion (SR) in a cohort of human immunodeficiency virus-exposed but uninfected infants. Groups of patients who seroreverted very early or late were examined for salient clinical and immunologic characteristics of the mother or infant. The mean time (+/- s.d.) to seroreversion by enzyme-linked immunoabsorbent assay (ELISA) was 50.1 +/- 14.8 weeks, or 11.6 months (n = 84); the range of times to antibody loss by ELISA was 17.9 to 82.0 weeks. The mean time to seroreversion by Western blot was 68.3 +/- 12.6 weeks, or 15.8 months (n = 51), with a range of 44.9 to 94.1 weeks. Initial anti-human immunodeficiency virus titer as measured by cord blood ELISA optical density (OD) was found to relate significantly to mean time to seroreversion. No relationship to time to seroreversion was demonstrated for gestational age, maternal or neonatal serum immunoglobulin concentrations, maternal CD4 cell counts, maternal alcohol consumption, infantile diarrhea or failure to thrive. The lengthy time to seroreversion seen here demonstrates the 1994 revised Centers for Disease Control and Prevention definition of human immunodeficiency virus infection (based on seropositivity by both ELISA and confirmatory tests persisting beyond 18 months of age) to be accurate in our population. We recommend Western blot testing be used as confirmation for positive ELISAs only after 18 months of age.
authors.affiliation: Department of Pediatrics, University of Puerto Rico School of Medicine, San Juan.
authors.forename: C J
authors.initials: CJ
authors.lastname: Chantry
authors.forename: E R
authors.initials: ER
authors.lastname: Cooper
authors.forename: S I
authors.initials: SI
authors.lastname: Pelton
authors.forename: C
authors.initials: C
authors.lastname: Zorilla
authors.forename: G V
authors.initials: GV
authors.lastname: Hillyer
authors.forename: C
authors.initials: C
authors.lastname: Diaz
mesh_terms: D015492:AIDS Serodiagnosis; D015153:Blotting, Western; D002391:Catchment Area, Health; D015331:Cohort Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015658:HIV Infections / Q000175:diagnosis / Q000276:immunology* / Q000635:transmission; D018023:HIV Seronegativity; D006679:HIV Seropositivity / Q000276:immunology; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology*; D011446:Prospective Studies